Canada markets closed

Kane Biotech Inc. (KNE.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.08500.0000 (0.00%)
At close: 02:32PM EST
Full screen
Previous Close0.0850
Open0.0850
Bid0.0800 x 0
Ask0.0850 x 0
Day's Range0.0850 - 0.0850
52 Week Range0.0800 - 0.1700
Volume6,000
Avg. Volume45,211
Market Cap10.611M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0420
Earnings DateNov 24, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kane Biotech Announces Third Quarter 2022 Financial Results

    Company Files First 510(k) Application in Wound CareWINNIPEG, Manitoba, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2022 financial results. Financial Highlights: Total revenue for the three months ended September 30, 2022 was $571,686 an increase of 5% compared to $541,302 in the three months ended September 30, 2021. In the nine months ended September 30, 2022, total revenue increased by 65% to

  • GlobeNewswire

    Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 – Conference Call to Follow

    WINNIPEG, Manitoba, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2022 financial results after market close on Thursday, November 24, 2022. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di

  • GlobeNewswire

    Kane Biotech Announces 510(k) Submission for its coactiv+™ Antimicrobial Hydrogel

    WINNIPEG, Manitoba, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that it has recently submitted a 510(k) premarket notification, which has been received by The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (“FDA”), for a new Wound Care coactiv+™ Antimicrobial Hydrogel. The Company’s device, which uses its patented coactiv+™ technology in a thermo-reversible gelling system, prov